Last updated on June 2018

PRASTERONE (DHEA) FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) - (PLACEBO-CONTROLLED, DOUBLE-BLIND AND RANDOMIZED PHASE III STUDY OF 24-WEEK INTRAVAGINAL PRASTERONE) - PROTOCOL ERC-242


Brief description of study

Sexual Dysfunction

Detailed Study Description

The objective of this study is to confirm the efficacy of intravaginal DHEA (also named prasterone) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women. We will also evaluate the effects of study treatment on the number of satisfying (pleasing) sexual events (SSEs). This study will last 28 weeks and involve a minimum of 6 visits at the clinic and 1 follow-up phone call. Some questionnaires will also need to be filled out at home using an electronic tablet.

Compensation for study visits may be provided to qualified study participants.

Clinical Study Identifier: TX154512

Find a site near you

Start Over

Pharmacology Research Institute, Los Alamitos

4281 Katella Avenue, Suite 115 Los Alamitos, CA USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.